Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted growth will slow this year. The Danish pharmaceutical company has ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Novo Nordisk reported soaring sales for weight loss drug Wegovy (James Manning/PA) Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo ...

Obesity drug maker Novo Nordisk NVO-N forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as “good ...

Share on Pinterest LeoPatrizi/Getty Images Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus. Currently, only Wegovy is approved for weight loss in the United States.

They include Trelegy Ellipta (asthma, COPD) and three big-name drugs for weight loss, diabetes and heart disease: Rybelsus, Ozempic and Wegovy. These negotiations would have to be implemented by ...